<DOC>
	<DOCNO>NCT00603304</DOCNO>
	<brief_summary>The CAMUS trial test Saw palmetto 369 men . Men decide part CAMUS trial give one two possible treatment random . One every two men would get inactive placebo treatment . One every two men would get Saw palmetto pill . This kind scientific study best way find plant extract really work prevent men benign prostatic hyperplasia ( BPH ) get bad . During study , men know two treatment assign . They follow closely study team every 12 week see . Men CAMUS trial study 72 week . Tests medication need part study provide charge participant . Participants responsible cost associate study test medication . All information study participant hold strict confidence one would access patient information require authorize health care research personnel .</brief_summary>
	<brief_title>Complementary Alternative Medicine Urological Symptoms ( CAMUS )</brief_title>
	<detailed_description>The CAMUS trial study outcome use herbal therapy benign prostatic hyperplasia ( BPH ) . BPH common problem old men . With BPH , prostate grows large . Over time , growth cause bothersome urinary symptom . These symptom include frequent and/or urgent urination day night . Men BPH also weak urine stream , stream stop start , feel empty bladder way , and/or need strain get urination start . BPH NOT prostate cancer . A number natural product ( extract different plant ) seem able reduce bothersome symptom BPH side effect month . One plant extract come dwarf palm tree ( Saw palmetto ) . The investigator know whether plant extract reduce symptom BPH long period treatment .</detailed_description>
	<mesh_term>Permixon</mesh_term>
	<criteria>To eligible study , potential participant must meet following eligibility criterion : 1 . Male least 45 year age . 2 . Peak urinary flow rate least 4 ml/sec void volume least 125 ml . 3 . AUA symptom score ≥ 8 ≤ 24 screen visit . 4 . Voluntarily sign informed consent agreement prior performance study procedure . Potential participant meet follow exclusion criterion exclude fullscale trial : 1 . Any prior invasive intervention BPH . 2 . Phytotherapy BPH 5alpha reductase inhibitor within 3 month . 3 . Alpha blocker within one month . 4 . Reported allergic reaction Serenoa repens . 5 . Taken phenylephrine , pseudoephedrine , tricyclic antidepressant , anticholinergic cholinergic medication within 4 week first screen visit , follow exception : topical anticholinergic eye drop use glaucoma . 6 . Taken estrogen , androgen , drug produce androgen suppression , anabolic steroid within 6 month . 7 . Known clinically significant renal impairment ( i.e. , creatinine great 2.0 mg/dl ) . 8 . Alanine aminotransferase ( ALT ) serum glutamic pyruvic transaminase ( SGPT ) , aspartate aminotransferase ( AST ) serum glutamic oxaloacetic transaminase ( SGOT ) gammaglutamyltranspeptidase ( GGT ) value great 3 time upper limit normal clinical center lab SV1.0 ; confirm second measurement . 9 . Prothrombin time great 3 second upper limit normal , 3 second control value clinical center SV1.0 ; confirm second measurement . 10 . Electrocardiogram ( ECG ) read clinical center SV1.0 suggest active ischemia recent myocardial infarction appropriate consultation confirms absence acute coronary syndrome . 11 . Prostatespecific antigen ( PSA ) level great 10 ng/ml first screen visit . 12 . Requires daily use pad device incontinence , International Continence Society male incontinence symptom ( ICSmaleIS ) score &gt; 14 screening . 13 . Unstable medical condition within past 3 month . 14 . History current evidence carcinoma prostate bladder , pelvic radiation surgery , urethral stricture , prior surgery bladder neck obstruction . 15 . Active urinary tract disease undergone cystoscopy biopsy prostate within one month prior first screen visit imminent need urologic surgery . 16 . Known primary neurologic condition multiple sclerosis Parkinson 's disease neurological disease know affect bladder function . 17 . Documented bacterial prostatitis within past year . 18 . Two documented independent urinary tract infection type past year . 19 . Known severe bleed disorder need ongoing therapeutic anticoagulation coumadin heparin . 20 . Cancer , consider cure ( except basal cell squamous cell carcinoma skin ) . A potential participant consider cured evidence cancer within five year randomization . A history bladder cancer prostate cancer exclusionary whether participant consider cure . 21 . Unable follow protocol direction due organic brain psychiatric disease . 22 . History alcoholism substance abuse , , opinion investigator , would affect compliance protocol . 23 . Any serious medical condition likely impede successful completion study .</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Serenoa repens</keyword>
	<keyword>Urological symptom</keyword>
	<keyword>hyperplasia</keyword>
	<keyword>BPH</keyword>
</DOC>